Factors associated with genetic testing in a cohort of breast cancer survivors.
Age Factors
Breast Neoplasms
/ genetics
Cancer Survivors
/ psychology
Causality
Cross-Sectional Studies
Female
Genetic Testing
/ statistics & numerical data
Health Services Accessibility
Humans
Middle Aged
Procedures and Techniques Utilization
/ statistics & numerical data
Socioeconomic Factors
Triple Negative Breast Neoplasms
/ genetics
United States
breast cancer
cancer genetic testing
pathogenic germline variant
Journal
The breast journal
ISSN: 1524-4741
Titre abrégé: Breast J
Pays: United States
ID NLM: 9505539
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
20
02
2019
revised:
08
03
2019
accepted:
12
03
2019
pubmed:
5
7
2019
medline:
11
4
2020
entrez:
5
7
2019
Statut:
ppublish
Résumé
We examined factors associated with self-reported use of genetic testing among breast cancer survivors based on a 2015 cross-sectional survey at eight Midwestern sites. Genetic testing was reported in 39% of our 1235 study participants, with higher utilization among those aged <50 and with a triple-negative cancer. Bilateral mastectomy, having relatives with breast cancer, and younger age were associated with increased genetic testing use. Increasing income, in interaction with age, was associated with use of genetic testing among younger but not older patients. Rural residency emerged as a possible barrier for genetic testing among women with triple-negative cancer.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1241-1244Subventions
Organisme : Patient-Centered Outcomes Research Institute
ID : CDRN-1306-04631
Pays : United States
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.
American Cancer Society A, Georgia. Breast cancer facts & figures 2015-2016. 2015; https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2015-2016.pdf. Accessed 6 June 2018.
Evans D, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140(1):135-142.
Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw. 2017;15(4):433-451.
Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800-3806.
Kurian AW, Griffith KA, Hamilton AS, et al. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017;317(5):531-534.
Whitworth P, Beitsch P, Arnell C, et al. Impact of payer constraints on access to genetic testing. J Oncol Pract. 2016;13(1):e47-e56.
Buchanan AH, Datta SK, Skinner CS, et al. Randomized trial of telegenetics vs. in-person cancer genetic counseling: cost, patient satisfaction and attendance. J Genet Couns. 2015;24(6):961-970.
Berger AM, Buzalko RJ, Kupzyk KA, Gardner BJ, Djalilova DM, Otte JL. Preferences and actual chemotherapy decision-making in the greater plains collaborative breast cancer study. Acta Oncol. 2017;56(12):1690-1697.
Rural Health Research Center, Department of Family Medicine, University of Washington. Rural-urban commuting area (RUCA) codes. RUCA data. Code definitions: Version 2.0. http://depts.washington.edu/uwruca/ruca-codes.php. Accessed 20 June 2018.
Halverson JL, Martinez-Donate AP, Palta M, et al. Health literacy and health-related quality of life among a population-based sample of cancer patients. J Health Commun. 2015;20(11):1320-1329.
Network N. Genetic/familial high-risk assessment: Breast and ovarian, version I 2018. 2017;https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.
Katz SJ, Ward KC, Hamilton AS, et al. Gaps in receipt of clinically indicated genetic counseling after diagnosis of breast cancer. J Clin Oncol. 2018;36(12):1218.
Barcenas CH, Shafaee MN, Sinha AK, et al. Genetic counseling referral rates in long-term survivors of triple-negative breast cancer. J Natl Compr Canc Netw. 2018;16(5):518-524.
Febbraro T, Robison K, Wilbur JS, et al. Adherence patterns to national comprehensive cancer network (NCCN) guidelines for referral to cancer genetic professionals. Gynecol Oncol. 2015;138(1):109-114.
Hamilton JG, Abdiwahab E, Edwards HM, Fang M-L, Jdayani A, Breslau ES. Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: a systematic review and research agenda. J Gen Intern Med. 2017;32(3):315-324.
Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017.
Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ. Awareness and utilization of BRCA1/2 testing among US primary care physicians. Am J Prev Med. 2011;40(1):61-66.
Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-533.